Charles River Laboratories Free Cash Flow 2010-2024 | CRL
Charles River Laboratories annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Charles River Laboratories free cash flow for the quarter ending March 31, 2024 was 50.74, a year-over-year.
- Charles River Laboratories free cash flow for the twelve months ending March 31, 2024 was , a year-over-year.
- Charles River Laboratories annual free cash flow for 2023 was $0.365B, a 23.89% increase from 2022.
- Charles River Laboratories annual free cash flow for 2022 was $0.295B, a 44.57% decline from 2021.
- Charles River Laboratories annual free cash flow for 2021 was $0.532B, a 40% increase from 2020.
| Charles River Laboratories Annual Free Cash Flow | |
|---|---|
| 2023 | 365.37 |
| 2022 | 294.91 |
| 2021 | 532.03 |
| 2020 | 380.02 |
| 2019 | 340.42 |
| 2018 | 301.09 |
| 2017 | 235.64 |
| 2016 | 261.61 |
| 2015 | 243.58 |
| 2014 | 195.21 |
| 2013 | 169.89 |
| 2012 | 160.47 |
| 2011 | 157.70 |
| 2010 | 125.38 |
| 2009 | 135.72 |
| Charles River Laboratories Quarterly Free Cash Flow | |
|---|---|
| 2024-03-31 | 50.74 |
| 2023-12-31 | 365.37 |
| 2023-09-30 | 222.75 |
| 2023-06-30 | 83.25 |
| 2023-03-31 | 2.51 |
| 2022-12-31 | 294.91 |
| 2022-09-30 | 149.17 |
| 2022-06-30 | 88.79 |
| 2022-03-31 | 22.17 |
| 2021-12-31 | 532.03 |
| 2021-09-30 | 401.54 |
| 2021-06-30 | 282.36 |
| 2021-03-31 | 142.20 |
| 2020-12-31 | 380.02 |
| 2020-09-30 | 329.49 |
| 2020-06-30 | 178.38 |
| 2020-03-31 | 42.87 |
| 2019-12-31 | 340.42 |
| 2019-09-30 | 223.58 |
| 2019-06-30 | 102.90 |
| 2019-03-31 | -1.87 |
| 2018-12-31 | 301.09 |
| 2018-09-30 | 229.79 |
| 2018-06-30 | 134.98 |
| 2018-03-31 | 32.33 |
| 2017-12-31 | 235.64 |
| 2017-09-30 | 139.91 |
| 2017-06-30 | 102.44 |
| 2017-03-31 | 18.11 |
| 2016-12-31 | 261.61 |
| 2016-09-30 | 168.64 |
| 2016-06-30 | 105.92 |
| 2016-03-31 | 37.59 |
| 2015-12-31 | 243.58 |
| 2015-09-30 | 150.89 |
| 2015-06-30 | 73.05 |
| 2015-03-31 | 0.60 |
| 2014-12-31 | 195.21 |
| 2014-09-30 | 122.38 |
| 2014-06-30 | 64.93 |
| 2014-03-31 | 17.27 |
| 2013-12-31 | 169.89 |
| 2013-09-30 | 121.23 |
| 2013-06-30 | 62.72 |
| 2013-03-31 | 23.55 |
| 2012-12-31 | 160.47 |
| 2012-09-30 | 109.88 |
| 2012-06-30 | 59.09 |
| 2012-03-31 | 11.17 |
| 2011-12-31 | 157.70 |
| 2011-09-30 | 113.27 |
| 2011-06-30 | 73.25 |
| 2011-03-31 | 14.60 |
| 2010-12-31 | 125.38 |
| 2010-09-30 | 73.92 |
| 2010-06-30 | 66.22 |
| 2010-03-31 | 18.64 |
| 2009-12-31 | 135.72 |
| 2009-09-30 | 91.75 |
| 2009-06-30 | 62.24 |
| 2009-03-31 | 12.49 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.751B | $4.129B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $125.315B | 15.72 |
| Cencora (COR) | United States | $44.797B | 17.47 |
| ICON (ICLR) | Ireland | $26.018B | 24.56 |
| DiDi Global (DIDIY) | China | $23.816B | 0.00 |
| Avantor (AVTR) | United States | $16.839B | 24.79 |
| CochLear (CHEOY) | Australia | $13.827B | 0.00 |
| Viatris (VTRS) | United States | $13.288B | 3.97 |
| Revvity (RVTY) | United States | $12.932B | 22.68 |
| Natera (NTRA) | United States | $12.715B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.253B | 0.00 |
| Medpace Holdings (MEDP) | United States | $12.089B | 39.78 |
| Solventum (SOLV) | United States | $10.996B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.479B | 0.00 |
| HealthEquity (HQY) | United States | $6.635B | 49.57 |
| Bausch + Lomb (BLCO) | Canada | $5.417B | 21.70 |
| Organon (OGN) | United States | $5.251B | 4.98 |
| Doximity (DOCS) | United States | $4.360B | 32.46 |
| PACS (PACS) | United States | $3.734B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.379B | 30.92 |
| Sotera Health (SHC) | United States | $3.125B | 15.33 |
| Life Times (LTH) | United States | $2.905B | 30.44 |
| Progyny (PGNY) | United States | $2.646B | 45.13 |
| GoodRx Holdings (GDRX) | United States | $2.607B | 94.29 |
| Premier (PINC) | United States | $2.336B | 8.74 |
| Agilon Health (AGL) | United States | $2.134B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.073B | 8.24 |
| Teladoc Health (TDOC) | United States | $2.027B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.926B | 0.00 |
| NovoCure (NVCR) | Jersey | $1.772B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.540B | 0.00 | |
| Alignment Healthcare (ALHC) | United States | $1.306B | 0.00 |
| Embecta (EMBC) | United States | $0.821B | 5.58 |
| CareDx (CDNA) | United States | $0.772B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.703B | 18.40 |
| Auna S.A (AUNA) | Luxembourg | $0.701B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.692B | 7.34 |
| InnovAge Holding (INNV) | United States | $0.555B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.542B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.537B | 0.00 |
| MultiPlan (MPLN) | United States | $0.455B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.447B | 0.00 |
| Enhabit (EHAB) | United States | $0.418B | 41.70 |
| LifeMD (LFMD) | United States | $0.394B | 0.00 |
| ModivCare (MODV) | United States | $0.373B | 6.98 |
| Beauty Health (SKIN) | United States | $0.338B | 0.00 |
| DocGo (DCGO) | United States | $0.315B | 16.78 |
| Sera Prognostics (SERA) | United States | $0.300B | 0.00 |
| Sharecare (SHCR) | United States | $0.280B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.269B | 0.00 |
| Biodesix (BDSX) | United States | $0.181B | 0.00 |
| So-Young (SY) | China | $0.131B | 44.00 |
| Oncology Institute (TOI) | United States | $0.069B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.068B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.052B | 0.00 |
| NeueHealth (NEUE) | United States | $0.051B | 6.84 |
| Co-Diagnostics (CODX) | United States | $0.035B | 0.00 |
| Nutex Health (NUTX) | United States | $0.031B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.031B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| OncoCyte (OCX) | United States | $0.024B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.023B | 0.00 |
| DermTech (DMTK) | United States | $0.022B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.010B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.005B | 0.00 |
| Assure Holdings (IONM) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |